As biosimilar competition nears for Roche and its subsidiary, Genentech, a new WARN notice in the state of California disclosed that Genentech is set to lay off 223 employees from a local plant beginning August 31, 2018.
As biosimilar competition nears for Roche and its subsidiary, Genentech, a new WARN notice posted in the state of California disclosed that Genentech is set to lay off 223 employees from a local plant beginning August 31, 2018.
“The success of our business depends on our ability to respond to change, appropriately allocate resources and manage our operations efficiently,” said a Genentech spokeswoman in a statement. The layoffs will be “across different departments” and will continue into November.
These cuts come less than a year after the company laid off 130 workers at its biologics plant in Vacaville, California. “We are making this organizational change in response to the current and anticipated production requirements, the volumes required for some of our new medicine formulations, and shift schedule adjustments,” said the company at the time.
Roche’s top selling cancer medications rituximab (Rituxan), trastuzumab (Herceptin), and bevacizumab (Avastin) together brought in the company more than $20 billion in 2017. The high earnings have identified the drugs as valuable targets for biosimilar developers.
Although the FDA has approved a trastuzumab biosimilar (Ogivri) and bevacizumab biosimilar (Mvasi), neither have yet reached the market. The United States came close this year to having an approved rituximab biosimilar, however, the drug developer (Sandoz) was issued a Complete Response Letter from the FDA in May.
Conversely, the European market has seen approvals and marketing efforts of biosimilars for all 3 reference products; including 1 biosimilar option for Avastin, 4 Herceptin biosimilars, and 6 Rituxan biosimilars (1 molecule marketed under 4 trade names, and another molecule marketed under 2 trade names).
Samsung Bioepis Report Signals Turning Point for US Biosimilars
May 1st 2025A wave of biosimilar approvals, aggressive pricing strategies, and a regulatory sea change are setting the stage for unprecedented momentum in the US biologics market, with 2025 already proving to be a landmark year in reshaping cost, access, and innovation across therapeutic areas.
How AI Can Help Address Cost-Related Nonadherence to Biologic, Biosimilar Treatment
March 9th 2025Despite saving billions, biosimilars still account for only a small share of the biologics market—what's standing in the way of broader adoption and how can artificial intelligence (AI) help change that?
Eye on Pharma: Sandoz Files Antitrust Suit; Yuflyma Interchangeability; Costco’s Ustekinumab Pick
April 22nd 2025Sandoz's antitrust suit against Amgen, the FDA’s interchangeability designation for Celltrion’s adalimumab biosimilar, and the inclusion of an ustekinumab biosimilar in Costco’s prescription program highlight growing momentum to expand biosimilar access and affordability for patients with chronic inflammatory diseases.
Will the FTC Be More PBM-Friendly Under a Second Trump Administration?
February 23rd 2025On this episode of Not So Different, we explore the Federal Trade Commission’s (FTC) second interim report on pharmacy benefit managers (PBMs) with Joe Wisniewski from Turquoise Health, discussing key issues like preferential reimbursement, drug pricing transparency, biosimilars, shifting regulations, and how a second Trump administration could reshape PBM practices.
Latest Biosimilar Deals Signal Growth Across Immunology, Oncology Markets
April 14th 2025During Q1 2025, pharmaceutical companies accelerated biosimilar expansion through strategic acquisitions and partnerships in hopes of boosting patient access to lower-cost treatments in immunology and oncology.